Tejara Capital Ltd Grows Position in Cardiol Therapeutics Inc. $CRDL

Tejara Capital Ltd increased its position in Cardiol Therapeutics Inc. (NASDAQ:CRDL) by 95.1% during the 4th quarter, Holdings Channel reports. The institutional investor owned 5,130,122 shares of the company’s stock after purchasing an additional 2,500,000 shares during the period. Cardiol Therapeutics makes up 1.2% of Tejara Capital Ltd’s holdings, making the stock its 17th biggest holding. Tejara Capital Ltd’s holdings in Cardiol Therapeutics were worth $4,893,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its position in Cardiol Therapeutics by 1,983.0% during the 3rd quarter. Bank of America Corp DE now owns 551,053 shares of the company’s stock valued at $590,000 after buying an additional 524,598 shares during the period. Citadel Advisors LLC increased its position in shares of Cardiol Therapeutics by 1,132.6% in the third quarter. Citadel Advisors LLC now owns 463,462 shares of the company’s stock valued at $496,000 after acquiring an additional 425,862 shares during the period. Two Sigma Investments LP purchased a new position in shares of Cardiol Therapeutics in the third quarter valued at about $249,000. Virtu Financial LLC bought a new position in shares of Cardiol Therapeutics during the third quarter valued at about $154,000. Finally, Susquehanna International Group LLP raised its stake in shares of Cardiol Therapeutics by 366.5% during the third quarter. Susquehanna International Group LLP now owns 93,398 shares of the company’s stock valued at $100,000 after acquiring an additional 73,375 shares during the last quarter. 12.49% of the stock is currently owned by institutional investors.

Cardiol Therapeutics Trading Up 0.7%

Shares of NASDAQ CRDL opened at $1.37 on Friday. The firm has a fifty day simple moving average of $1.26 and a two-hundred day simple moving average of $1.10. Cardiol Therapeutics Inc. has a 12 month low of $0.88 and a 12 month high of $1.71. The firm has a market capitalization of $153.19 million, a PE ratio of -4.89 and a beta of 0.77.

Cardiol Therapeutics (NASDAQ:CRDL) last announced its earnings results on Monday, May 11th. The company reported ($0.07) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.07). On average, sell-side analysts predict that Cardiol Therapeutics Inc. will post -0.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. raised Cardiol Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 3rd. Wall Street Zen raised Cardiol Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, April 5th. HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Cardiol Therapeutics in a report on Tuesday, February 10th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $8.00 price objective on shares of Cardiol Therapeutics in a research report on Monday, April 6th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $8.50.

About Cardiol Therapeutics

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.